Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ARMP

ARMP - Armata Pharmaceuticals Inc Stock Price, Fair Value and News

2.91USD+0.07 (+2.46%)Delayed as of 21 Feb 2024, 01:01 pm ET
Watchlist

Market Summary

USD2.91+0.07
Delayedas of 21 Feb 2024, 01:01 pm
2.46%

ARMP Stock Price

View Fullscreen

ARMP RSI Chart

ARMP Valuation

Market Cap

102.7M

Price/Earnings (Trailing)

-1.72

Price/Sales (Trailing)

31.17

EV/EBITDA

-5.54

Price/Free Cashflow

-1.86

ARMP Price/Sales (Trailing)

ARMP Profitability

EBT Margin

-478.60%

Return on Equity

-21.54%

Return on Assets

-52.78%

Free Cashflow Yield

-53.67%

ARMP Fundamentals

ARMP Revenue

Revenue (TTM)

4.1M

Rev. Growth (Yr)

-8.45%

Rev. Growth (Qtr)

25%

ARMP Earnings

Earnings (TTM)

-59.5M

Earnings Growth (Yr)

-261.75%

Earnings Growth (Qtr)

-778.52%

Breaking Down ARMP Revenue

52 Week Range

1.075.26
(Low)(High)

Last 7 days

-23.2%

Last 30 days

-21.2%

Last 90 days

32.4%

Trailing 12 Months

7.5%

How does ARMP drawdown profile look like?

ARMP Financial Health

Current Ratio

1.67

ARMP Investor Care

Shares Dilution (1Y)

0.01%

Diluted EPS (TTM)

-1.72

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000
20220000
20211.9M3.1M4.1M0
2020000823.0K
20190000
20180000
2017183.0K108.0K117.0K115.0K
2016479.0K480.0K366.0K260.0K
2015407.0K408.0K448.0K475.0K
2014163.0K245.0K327.0K409.0K
201300081.0K

Tracking the Latest Insider Buys and Sells of Armata Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 21, 2023
birx deborah
acquired
-
-
200,000
chief executive officer
Mar 31, 2022
innoviva, inc.
bought
26,926,000
5.00
5,385,210
-
Feb 09, 2022
innoviva, inc.
bought
18,074,000
5.00
3,614,790
-
Oct 29, 2021
innoviva, inc.
bought
4,000,000
3.3
1,212,120
-
Mar 17, 2021
innoviva, inc.
bought
13,929,300
3.25
4,285,940
-
Jan 26, 2021
innoviva, inc.
bought
6,070,710
3.25
1,867,910
-
Mar 27, 2020
innoviva, inc.
bought
22,149,700
2.87
7,717,660
-

1–7 of 7

Which funds bought or sold ARMP recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 14, 2024
STATE STREET CORP
unchanged
-
9,672
130,572
-%
Feb 14, 2024
BANK OF AMERICA CORP /DE/
added
-
152,290
2,055,620
-%
Feb 14, 2024
Team Financial Group, LLC
unchanged
-
17.00
230
-%
Feb 14, 2024
CAPTRUST FINANCIAL ADVISORS
unchanged
-
3,252
43,896
-%
Feb 14, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC
reduced
-31.18
-123,508
357,638
0.01%
Feb 14, 2024
VANGUARD GROUP INC
added
59.48
197,145
470,052
-%
Feb 14, 2024
Royal Bank of Canada
added
1,466
1,000
1,000
-%
Feb 13, 2024
GEODE CAPITAL MANAGEMENT, LLC
unchanged
-
24,242
327,365
-%

1–10 of 29

Are Funds Buying or Selling ARMP?

Are funds buying ARMP calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ARMP
No. of Funds

Unveiling Armata Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jul 11, 2023
innoviva, inc.
85.3%
64,178,259
SC 13D/A
Jan 10, 2023
innoviva, inc.
85.3%
64,178,259
SC 13D/A
Apr 01, 2022
innoviva, inc.
80.1%
44,441,416
SC 13D/A
Feb 11, 2022
innoviva, inc.
76.7%
36,363,604
SC 13D/A
Nov 01, 2021
innoviva, inc.
73.8%
30,941,416
SC 13D/A
Apr 05, 2021
innoviva, inc.
-
0
SC 13D/A
Mar 17, 2021
innoviva, inc.
74.7%
29,729,294
SC 13D/A
Jan 27, 2021
innoviva, inc.
68%
21,157,424
SC 13D/A
Mar 31, 2020
innoviva, inc.
63.7%
17,421,600
SC 13D/A
Feb 14, 2020
innoviva, inc.
16.66%
1,986,278
SC 13D

Recent SEC filings of Armata Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Jan 23, 2024
S-8
Employee Benefits Plan
Dec 26, 2023
4
Insider Trading
Dec 26, 2023
4
Insider Trading
Dec 26, 2023
4
Insider Trading
Dec 26, 2023
4
Insider Trading
Dec 26, 2023
4
Insider Trading
Dec 26, 2023
4
Insider Trading
Dec 26, 2023
4
Insider Trading
Dec 26, 2023
4
Insider Trading
Nov 15, 2023
S-8
Employee Benefits Plan

Peers (Alternatives to Armata Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
33.2B
9.1B
-16.59% -47.80%
-9.57
3.64
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
18.9B
1.8B
-23.99% -31.71%
-42.82
10.31
76.23% 61.08%
16.7B
2.3B
-4.89% -18.90%
113.61
7.23
15.05% 75.21%
13.2B
3.7B
-7.62% -26.87%
22.1
3.57
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.27
29.46
141.38% 4.43%
6.3B
107.9M
-3.85% 226.12%
-10.03
54.1
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-19.02
17.18
-35.86% -26.24%
3.6B
240.7M
-19.08% -10.99%
-12.2
15.04
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.7
4.22
81.69% -7.29%
490.6M
1.0B
-9.17% -57.89%
-0.89
0.47
-43.15% 58.48%
185.9M
4.9M
-14.18% -58.18%
-1.13
38.02
-57.57% 50.48%
103.1M
881.7K
289.54% 381.25%
-2.17
112.79
-77.61% -13.74%
4.4M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Armata Pharmaceuticals Inc News

Latest updates
Morningstar7 hours ago

Armata Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q22019Q42019Q32019Q22019Q12018Q42018Q3
Revenue25.0%1,225,000980,000796,0001,067,0001,338,0001,883,0001,236,0001,268,0001,300,0001,200,0001,066,000504,000288,00031,000-------
Operating Expenses9.0%11,561,00010,609,00012,142,00011,379,0009,961,00011,103,00010,011,0007,037,0007,394,0007,364,0006,501,0006,957,0005,911,0004,621,000-4,293,5006,777,0005,158,0003,606,0006,062,5002,429,000
  S&GA Expenses52.5%3,583,0002,350,0002,538,0001,810,0001,561,0002,083,0001,983,0002,223,0001,768,0002,139,0002,151,0001,977,0001,845,0001,973,000-2,045,0003,758,0002,082,0001,380,000333,500514,000
  R&D Expenses------------92,000292,000138,000-7,225,000356,000749,0001,494,0004,855,000361,000
EBITDA Margin0%-4.56-4.56-4.56-4.57-4.55-4.52-4.50-4.48-4.45-5.88-9.44-21.55---------
Interest Expenses-1,176,000-------2,000-62,000152,500150,000142,000-205,000190,000230,000306,000324,000307,000
Earnings Before Taxes-----------------4,586,000-6,955,000-4,199,000--1,101,000-2,771,000
EBT Margin0%-4.79-4.79-4.79-4.79-4.79-4.79-4.79-4.79-4.79-6.37-10.31-23.67---------
Net Income-778.5%-31,161,000-3,547,000-14,490,000-10,314,000-8,614,000-9,215,000-8,774,000-6,047,000-5,419,000-6,194,000-5,495,000-6,624,000-5,769,000-4,710,000--4,586,000-6,955,000-4,199,000-3,739,000-4,365,500-2,771,000
Net Income Margin-61.0%-14.62-9.08-10.47-9.07-8.02-7.24-6.49-5.69-5.83-7.88-11.96-26.95---------
Free Cashflow-7.5%-13,199,000-12,282,000-19,580,000-10,030,000-11,627,000-9,284,000-3,751,000-8,826,000-5,546,000-4,734,000-5,773,000-6,668,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets11.4%11310110996.0093.0010110870.0043.0048.0053.0040.0046.0049.0044.0025.0029.0035.0010.0015.0011.00
  Current Assets36.3%37.0027.0039.0027.0033.0041.0049.0015.0014.0020.0024.0011.0017.0021.0026.007.0010.0014.006.0010.005.00
    Cash Equivalents92.3%24.0012.0025.0015.0025.0037.0046.0011.0012.0018.0022.0011.0016.0020.0024.007.009.0013.006.0010.0013.00
  Net PPE5.0%9.009.005.004.004.003.002.002.002.002.002.002.002.002.002.002.003.003.000.003.001.00
  Goodwill0%3.003.003.003.003.003.003.003.003.003.003.003.003.003.003.003.003.003.00---
Liabilities52.5%12582.0086.0060.0047.0048.0046.0044.0019.0020.0019.0021.0021.0020.0011.0011.0011.0012.005.007.004.00
  Current Liabilities-57.6%22.0052.0051.0025.007.007.006.005.005.006.005.007.007.005.006.005.005.006.004.002.002.00
Shareholder's Equity1343.0%27619.0022.0036.0046.0053.0062.0025.0024.0029.0034.0019.0025.0030.0033.0015.0018.0023.004.008.009.00
  Retained Earnings-12.1%-288-257-254-239-229-220-211-202-196-191-185-179-173-167-162-157-152-145-409-138-402
  Additional Paid-In Capital-0.1%276277276275275274273228220220219198198197196172171169415146409
Shares Outstanding0.0%36.0036.0036.0036.0034.0033.0029.0027.0023.0025.0020.0019.00---------
Float------42.00---39.00---38.00---39.00---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations19.7%-9,687-12,060-17,570-10,485-10,333-8,148-3,515-8,598-4,964-4,538-5,475-6,302-3,880-3,856-4,232-2,729-4,567-5,827-2,459-3,195-2,020
  Share Based Compensation-242.9%-3732618578178469494936644699078428626639061,0441,0472,49962699.00-1.008.00
Cashflow From Investing-1482.0%-3,512-222-2,010455-1,294-1,136-236-228-582-196-298-366-81.00-273-10472.0065.002,882-142-535-11.00
Cashflow From Financing6840.5%24,805-36829,594-50031.00-14644,6317,03886.00-18518,57943260.0030622,412--9,975-1,0006,089-44.00

ARMP Income Statement

2023-09-30
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Condensed Consolidated Statements of Operations    
Grant revenue$ 1,225,000$ 1,338,000$ 3,001,000$ 4,457,000
Operating expenses    
Research and development7,978,0008,400,00025,842,00025,448,000
General and administrative3,583,0001,561,0008,470,0005,627,000
Total operating expenses11,561,0009,961,00034,312,00031,075,000
Loss from operations(10,336,000)(8,623,000)(31,311,000)(26,618,000)
Other income (expense)    
Interest income47,0009,000111,00015,000
Interest expense(1,176,000) (1,176,000) 
Change in fair value of convertible debt(15,833,000) (12,959,000) 
Loss on convertible debt extinguishment(3,863,000) (3,863,000) 
Total other income (expense), net(20,825,000)9,000(17,887,000)15,000
Net loss$ (31,161,000)$ (8,614,000)$ (49,198,000)$ (26,603,000)
Per share information:    
Net loss per share, basic (in dollars per share)$ (0.86)$ (0.24)$ (1.36)$ (0.79)
Net loss per share, diluted (in dollars per share)$ (0.86)$ (0.24)$ (1.36)$ (0.79)
Weighted average shares outstanding, basic (in shares)36,086,99036,038,68636,067,02533,704,071
Weighted average shares outstanding, diluted (in shares)36,086,99036,038,68636,067,02533,704,071

ARMP Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 23,958,000$ 14,852,000
Prepaid expenses4,130,0003,664,000
Other receivables8,497,0008,531,000
Total current assets36,585,00027,047,000
Restricted cash5,824,0005,960,000
Property and equipment, net9,250,0003,617,000
Operating lease right-of-use asset44,886,00043,035,000
In-process research and development10,256,00010,256,000
Goodwill3,490,0003,490,000
Other assets2,470,0002,429,000
Total assets112,761,00095,834,000
Current liabilities  
Accounts payable and accrued liabilities6,700,0006,034,000
Accrued compensation1,741,0001,828,000
Current portion of operating lease liabilities13,443,00017,011,000
Total current liabilities21,884,00024,873,000
Operating lease liabilities, net of current portion28,162,00031,804,000
Convertible debt49,747,000 
Long-term debt22,277,000 
Deferred tax liability3,077,0003,077,000
Total liabilities125,147,00059,754,000
Shareholders' (deficit) equity  
Common stock, $0.01 par value; 217,000,000 shares authorized; 36,122,591 and 36,144,706 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively361,000361,000
Additional paid-in capital276,225,000275,493,000
Accumulated deficit(288,972,000)(239,774,000)
Total shareholders' (deficit) equity(12,386,000)36,080,000
Total liabilities and shareholders' (deficit) equity$ 112,761,000$ 95,834,000
ARMP
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
 CEO
 WEBSITEwww.armatapharma.com
 EMPLOYEES72

Armata Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Armata Pharmaceuticals Inc? What does ARMP stand for in stocks?

ARMP is the stock ticker symbol of Armata Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Armata Pharmaceuticals Inc (ARMP)?

As of Tue Feb 20 2024, market cap of Armata Pharmaceuticals Inc is 102.66 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ARMP stock?

You can check ARMP's fair value in chart for subscribers.

What is the fair value of ARMP stock?

You can check ARMP's fair value in chart for subscribers. The fair value of Armata Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Armata Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ARMP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Armata Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ARMP is over valued or under valued. Whether Armata Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Armata Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARMP.

What is Armata Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Feb 20 2024, ARMP's PE ratio (Price to Earnings) is -1.72 and Price to Sales (PS) ratio is 31.17. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARMP PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Armata Pharmaceuticals Inc's stock?

In the past 10 years, Armata Pharmaceuticals Inc has provided -0.27 (multiply by 100 for percentage) rate of return.